AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05783245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polarcare Machine
Description: Use of Polar Care ice machine as often as possible, but a minimum of three 15 minute uses per day, for the first 3 days after surgery. No single use should last longer than 30 minutes.
Study NCT05783245 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care ice therapy
Description: Use of commercial reusable ice packs as often as possible, but a minimum of three 15 minute uses per day, for the first 3 days after surgery. No single use should last longer than 30 minutes.
Study NCT05305807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postural exercises
Description: Postural correction exercises are effective in improving forward head posture and it effectively decrease neck pain and increase ROM Exercise training and ergonomic guidelines concerning the use of touchscreen smartphones will reduce the risk of developing upper extremity musculoskeletal disorders
Study NCT06106672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNP-106
Description: CNP-106 is comprised of an antigenic AChR Peptide Pool (\~1 μg of each AChRα and AChRε peptide comprising AChR Peptide Pool Drug Substance per mg particles) dispersed within a negatively charged (-30 to -60 mV) polymer matrix of PLGA (Poly (DL-lactide-co-glycolide, 50:50 acid-end group)) particles (400-800 nm in size).
Study NCT06106672 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: CNP-106 Placebo
Study NCT04634266 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter tricuspid valve treatment (TTVT)
Description: Percutaneous CE-mark approved techniques for transcatheter tricuspid valve treatment (TTVT): These include (I) transcatheter annuloplasty devices (Tricuspid Cardioband) and (II) transcatheter edge-to-edge repair (TriClip, PASCAL).
Study NCT05344469 — intervention group
Intervention type: OTHER
Intervention: ofatumumab
Description: There is no treatment allocation. Patients administered ofatumumab by prescription that have started as routine medical treatment will be enrolled.
Study NCT05344469 — intervention group
Intervention type: OTHER
Intervention: glatiramer acetate
Description: There is no treatment allocation. Patients administered glatiramer acetate by prescription that have started as routine medical treatment will be enrolled.
Study NCT05344469 — intervention group
Intervention type: OTHER
Intervention: interferon β1
Description: There is no treatment allocation. Patients administered interferon β1 by prescription that have started as routine medical treatment will be enrolled.
Study NCT06075706 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MC0518
Description: MC0518 will be intravenously infused immediately after thawing.
Study NCT06075706 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BAT
Description: BAT including ECP, ATG, etanercept, infliximab or RUX will be administered based on Investigator's decision.
Study NCT04184635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VA-ECMO
Description: * The ECMO device will be the CardioHelp (MAQUET, GETINGE, Orléans, France) using the veno-arterial setting and percutaneous femoro-femoral cannulation with MAQUET GETINGE HLS cannulae.~* Intraortic balloon pump will be MEGA 50 cc or 40cc, (MAQUET, GETINGE, Orléans, France).
Study NCT04316169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: 150 mg b.i.d
Study NCT04316169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 200 mg
Description: Dose level: 200 mg b.i.d.
Study NCT04316169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faslodex
Description: Cohort B will receive Faslodex.
Study NCT04316169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrazole
Description: Cohort A will receive anastrazole or letrozole.
Study NCT04316169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Cohort A will receive anastrazole or letrozole.
Study NCT04316169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 400 mg
Description: Dose level: 400 mg. b.i.d.
Study NCT04316169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 600 mg
Description: Dose level: 600 mg b.i.d.
Study NCT06489717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SDB assessment
Description: SDB will be assessed by respiratory polygraphy according to clinical standards
Study NCT06581003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen 99.7 %
Description: The experimental group will undergo HBOT in a specialized chamber at a pressure of 2.0 ATA. Oxygen will be delivered at 100% for 60 minutes.
Study NCT06581003 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Oxygen 21 %
Description: The control group will be placed in the same specialized chamber, but pressure will be 1.0 ATA (normobaric), and oxygen will be delivered at 21% (normal oxygen concentration in room air) for 60 minutes.
Study NCT04995484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Two 40 mg tablets given as a single oral 80 mg dose.
Study NCT05446662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music therapy
Description: Patients participating in the study will be informed about the application of music therapy in the preoperative period. The patients who will take part in the music group are given 30 minutes the day before the surgery, and 30 minutes a day on the 1st and 2nd days after the surgery. Music that is selected by the researcher and grouped as relaxing music, classical music, sufi music and Turkish folk music will be played. The patients will be listened to the music with headphones that cover the whole ear, and the music will be adjusted to make them feel comfortable.
Study NCT05446662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aromatherapy
Description: Patients participating in the study will be informed about the application of aromatherapy in the preoperative period. During this period, patients undergo elbow test (1 drop of lavender oil will be dripped onto the inside of the patient's elbow, after 20 minutes, it will be evaluated whether an allergic reaction has developed). Lavender oil as aromatic oil will be administered to the patients in the aromatherapy group in the form of inhalation. Lavender oil inhalation (1 drop of 0.1 cc) It will be applied by inhalation with gauze on which 3-4 drops of lavender oil are poured. 30 minutes before surgery. Aromatherapy will be applied four times with an interval of 30 seconds on the 1st and 2nd days before and after the surgery.
Study NCT05446662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Relaxation Exercises
Description: Patients participating in the study will be informed about relaxation exercises in the preoperative period. Progressive relaxation training will be applied to the patients for 30 minutes once a day, on the day before the operation and on the 1st and 2nd days after the operation.
Study NCT05446662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand massage
Description: Patients participating in the study will be informed about the application of massage therapy in the preoperative period. 10-15 minutes once in the preoperative period. And in the postoperative period, the 1st and 2nd days are 10-15 minutes. application will be carried out. Lavender oil (Lavandula Angustifolia) will be used in hand massage, sweet almond oil (Prunus Amygladus Sativa) will be used as essential oil.
Study NCT06565481 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Measurement Properties (Reliability and Validity) of a Set of Assessments evaluating Physical Function in adult Participants with Hemophilia
Description: This study evaluates the reliability (Test-Retest) of six health related instruments that assess physical function in people with hemophilia: Short Physical Performance Battery, Unipedal Stance Test, Four Square Step Test, Timed up and Go, 1 kg Arm Lift Test, 30 Second Chair Stand Test. This study is needed to determine the psychometric properties of these six assessments. Validity of these test will be determined with the Short Form 36, the Hemophilia Activities List and the Hemophilia Joint Health Score Methodology: Reliability (Test re-test study and validity (cross sectional study) of the six tests reported in patients with hemophilia.~This intervention contains physiotherapie assessments, however, no drugs nor medical devices.
Study NCT06114940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg, IV (in the vein) on on day 1 of 3-week, 6-week and 9-week for a total of 3 doses prior to partial nephrectomy or radical nephrectomy
Study NCT06114940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 20 mg by mouth once each day for 12 weeks prior to nephrectomy
Study NCT06539741 — intervention group
Intervention type: DRUG
Intervention: Ibuprofen 400 mg
Description: 400 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction
Study NCT06539741 — intervention group
Intervention type: DRUG
Intervention: Acetaminophen 500mg
Description: 500 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction
Study NCT06539741 — intervention group
Intervention type: DRUG
Intervention: OxyCODONE 5 mg Oral Tablet
Description: 5 mg by mouth every 6 hours as needed for pain
Study NCT06191900 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous tumor infiltrating lymphocyte injection（GT201）
Description: GT201 treatment for advanced gynecological tumors (advanced cervical cancer)
Study NCT06266052 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Triangular Flap
Description: Triangular flap is a type of flap that is made in the retromolar region, from the distal of the 2nd molar tooth towards the ramus and up to the distal gingival sulcus of the 2nd molar, and includes a vertical releasing incision added from the distobuccal sulcus of the 2nd molar tooth. The auxiliary vertical incision made in this flap type allows the wound to be closed without tension.
Study NCT06266052 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Berwick Flap
Description: Berwick described a type of flap whose base is in the distolingual direction of the second molar tooth, in which the tongue-shaped vestibular wing extends to the buccal part of the mandible. In this modification, the incision line is not over the bone defect created by the extraction.
Study NCT06266052 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saurez Flap
Description: In the modified flap type he used, Suarez combined the crestal incision (marginal incision) from the distobuccal corner of the second molar tooth, following the line where the retromolar area meets the buccal bone, with a releasing incision made at the mesial and distal ends of the incision.
Study NCT06266052 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heitz Flap
Description: Heitz used the incision line extending from the distobuccal corner of the 2nd molar tooth to the buccal face of the 2nd molar tooth and downwards, by rotating it towards the angulus mandible on the buccal bone.
Study NCT05738525 — intervention group
Intervention type: DEVICE
Intervention: APD-RPM
Description: APD mode is recommended but not limited to continuous circulating peritoneal dialysis (CCPD); (2) Dialysis dose ranges from 5 to 10 liters per day and depends on previous APD prescription and dialysis adequacy; (3) Glucose concentration starts from low concentration (1.5%) and depends on previous dialysis prescription.~Remote monitoring includes dynamic changes of the overall treatment situation, warning or any abnormal notes, and drainage, retention and duration of APD per day.
Study NCT05642494 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SDF
Description: Silver Diamine Fluoride 38% (Applied bianually)
Study NCT05642494 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SDF
Description: Silver Diamine Fluoride 38% (Applied bianually)
Study NCT05642494 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NaF
Description: Sodium Fluoride Varnish (5%) (Applied at baseline and after 3 months)
Study NCT04420364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maintenance or reduction of immunosuppression
Description: Maintenance versus reduction of immunosuppression
Study NCT04420364 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance or reduction of immunosuppression
Description: Maintenance versus reduction of immunosuppression
Study NCT05116774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX9930
Description: Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily
Study NCT05116774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eculizumab
Description: Administered by intravenous infusion per current dose regimen
Study NCT05116774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ravulizumab
Description: Administered as intravenous infusion per current dose regimen
Study NCT06298071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIBP-R002
Description: Injection; strength: 4mg. Each group consists of 12 participants. Firstly, 4 sentinel participants were enrolled in the single dose phase of peruricase for injection and methotrexate. After the sentinel participants completed a 5-day safety observation of the single dose, the remaining 8 participants in this group can be enrolled simultaneously. If there are no special circumstances, the participants in this group will enter the multi-dose stage of peruricase for injection combined with methotrexate within 2-4 weeks after completing a single dose.
Study NCT06298071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIBP-R002
Description: Injection; strength: 8mg. Each group consists of 12 participants. Firstly, 4 sentinel participants were enrolled in the single dose phase of peruricase for injection and methotrexate. After the sentinel participants completed a 5-day safety observation of the single dose, the remaining 8 participants in this group can be enrolled simultaneously. If there are no special circumstances, the participants in this group will enter the multi-dose stage of peruricase for injection combined with methotrexate within 2-4 weeks after completing a single dose.
Study NCT06298071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIBP-R002
Description: Injection; strength: 12mg. Each group consists of 12 participants. Firstly, 4 sentinel participants were enrolled in the single dose phase of peruricase for injection and methotrexate. After the sentinel participants completed a 5-day safety observation of the single dose, the remaining 8 participants in this group can be enrolled simultaneously. If there are no special circumstances, the participants in this group will enter the multi-dose stage of peruricase for injection combined with methotrexate within 2-4 weeks after completing a single dose.
Study NCT06298071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Combination drugs: Methotrexate, dose15 mg, oral.
Study NCT05297032 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quercetin Phytosome
Description: All participants will ingest 1 capsule of Quercetin Phytosome (250 mg) three times daily with meals for 90 days.
Study NCT06214208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Spinal Stimulation
Description: Transcutaneous spinal stimulation will be delivered for 30 minutes using biphasic pulses. A single cathode electrode will be placed over the skin of the back spine at the T11/T12 spinous interspace. Two reference electrodes will be placed over the stomach. Stimulation intensity will be set to 0.8x reflex threshold, as determined by posterior root muscle reflex testing before the intervention. Treatments will be a minimum of 72 hours apart.
Study NCT04491175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M-Stim
Description: The casing for the device is a 54 belt with 3-button haptic controller for on-off, therapy cycles(8) and intensity(5) levels.
Study NCT04491175 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: LG SMART TENS stimulator is a portable electrotherapy devcie featuring transcutaneous electrical nerve stimulation (TENS) therapeutic device, which is used for pain relief. The stimulator sends a gentle electrical current to underlying nerves and muscle groups via electrodes applied on the skin. The parameters of the device are controlled by buttons on a controller with an adjustable intensity level.
Study NCT05405309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-3500
Description: RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity.
Study NCT05405309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is an oral poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that inhibits PARP's function by competitively binding to the Nicotinamide adenine dinucleotide (NAD+) binding site, which PARP requires as a cofactor to operate.
Study NCT05392452 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CamAPS HX
Description: Fully automated closed-loop subcutaneous insulin delivery system. A model predictive controller modulates insulin delivery every 10-12 minutes based on interstitial glucose measurements.
Study NCT05392452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard insulin therapy
Description: Standard insulin therapy according to local clinical practice.
Study NCT05437809 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intake of nutritionally diverse ultra-processed foods
Description: All participants will attend four food consumption assessment visits where, at each visit, they will be asked to consume a standardized snack portion of: 1) ultra-processed foods (UPFs) high in both fat and refined carbohydrates (UPF+FRC), 2) UPF high in fat (UPF+F), 3) UPF high in refined carbohydrates (white flour, sugar) (UPF+RC), or 4) minimally processed foods. The order of the four food consumption assessment visits will be randomized and counterbalanced across participants, who will each consume all the test snacks across the four appointments.
Study NCT04807270 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular T-LAB / PRP KIT injection
Description: Intra-articular 3 ml T-LAB / PRP KIT injection in 3 sessions will be applied. As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions.
Study NCT04807270 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular T-LAB / PRP INJECTION SYRINGE injection
Description: Intra-articular 3 ml T-LAB / PRP INJECTION SYRINGE injection in 3 sessions will be applied. As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions.
Study NCT04807270 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular SALINE injection
Description: Intra-articular 3 ml SALINE injection in 3 sessions will be applied. As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions.
Study NCT04873310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Triple P online with professional support
Description: The psychologist in charge will have the role of monitoring the autonomous work of the participants during the 8 sessions. The psychologist in charge will also verify that the participants are able to complete the online modules week by week, that they understand the contents taught in the module and that they are practicing the tasks and exercises assigned in each of the modules; in addition to generating an action plan in case the participants are not adhering week by week to the self-administration of the program. The follow-up and contact with the families will be carried out by phone and through a weekly email-type messaging system, implemented within the same platform on which the program material is found
Study NCT04873310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Triple P online without professional support
Description: The role of the psychologist in charge will be to keep the platform updated so that the person who self-administers the intervention does not have technical problems associated with the platform.
Study NCT06639607 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEP-CMV vaccine
Description: Intra-dermally administered half in the RIGHT groin and half in the LEFT groin.
Study NCT06639607 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus booster
Description: Td 5 flocculation units, Lf
Study NCT06639607 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered intravenously
Study NCT06639607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Administered orally
Study NCT05732766 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hillchol vaccine
Description: Hillchol® (BBV131) (The whole cell inactivated Stable Hikojima expressing both Inaba and Ogawa LPS) inactivated bacteria of a stable recombinant Vibrio cholerae O1 El Tor Hikojima serotype strain expressing approximately 50% each of Ogawa and Inaba O1 LPS antigens.
Study NCT06270979 — intervention group
Intervention type: DEVICE
Intervention: ISHA
Description: Participants will be provided with an Eforto® device and ISHA mobile application to self-monitor intrinsic capacity for 4 months (if needed with assistance by an (in)formal caregiver).